Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Radiation Oncology

Barbara Alicja Jereczek-Fossa¹  Stefano Arcangeli²  Stefanie Corradini³  Maria Tolia⁴  Rosario Mazzola⁵  Filippo Alongi⁵  Slavisa Tubin⁶  Giuseppe Minniti⁷  Andrea Riccardo Filippi⁸  Andrea Lancia⁸  Davide Franceschini⁹  Marta Scorsetti⁹ 

[1] Department of Radiation Oncology IEO, European Institute of Oncology IRCCS;Department of Radiation Oncology, Policlinico S. Gerardo and University of Milan “Bicocca”;Department of Radiation Oncology, University Hospital, LMU Munich;Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa;IRCCS, Advanced Radiation Oncology Department, Sacro Cuore Don Calabria Hospital;KABEG Klinikum Klagenfurt, Institute of Radiation Oncology;Radiation Oncology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena;Radiation Oncology, Fondazione IRCCS Policlinico San Matteo;Radiotherapy and Radiosurgery Department, Humanitas Cancer Center;

关键词: Oligometastasis;    Immunotherapy;    Target therapy;    Metastases-directed therapy;   

DOI  :  10.1186/s13014-020-01544-0

来源: DOAJ

【 摘 要 】

Abstract Background During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer. Material and method Narrative Review regarding retrospective and prospective studies published between January 2009 to November 2019 with at least 20 patients analyzed. Results Concerning the combination between SBRT and Immunotherapy, the correct sequence of remains uncertain, and seems to be drug-dependent. The optimal patients’ selection is crucial to expect substantial benefits to SBRT/Immunotherapy combination and, among several factors. A potential field of interest is represented by the so-called oligoprogressed disease, in which SBRT could improve the long-term efficacy of the existing target therapy. Conclusions A low tumor burden seems to be the most relevant, thus making the oligometastatic disease represent the ideal setting for the use of combination therapies with immunological drugs.

【 授权许可】

Unknown